The Experts below are selected from a list of 14172 Experts worldwide ranked by ideXlab platform

Anne Segolene Cottereau - One of the best experts on this subject based on the ideXlab platform.

  • Predictive value of PET response combined with baseline metabolic tumor volume in Peripheral T-Cell Lymphoma patients
    Journal of Nuclear Medicine, 2018
    Co-Authors: Anne Segolene Cottereau, Herve Tilly, S. Becker, F. Broussais, C. Bonnet, Tarec C El-galaly, Lars Jelstrup Peterson, John O Prior, Martin Hutchings, Olivie Casasnovas
    Abstract:

    Peripheral T-Cell Lymphoma (PTCL) is a heterogeneous group of aggressive non-Hodgkin Lymphomas with poor outcomes with current therapy. We investigated if response assessed with Positron Emission Tomography/computed tomography (PET/CT) combined with baseline total metabolic tumor volume (TMTV) could detect early relapse/refractory patients. Methods: 140 patients with nodal PTCL who underwent baseline PET/CT were selected from 7 European centers. 43 had interim PET (iPET) performed after two cycles (iPET2), 95 after 3 or 4 cycles (iPET3/4) and 96 had end of treatment PET (eotPET). Baseline TMTV was computed with 41% SUVmax threshold, and PET response was reported with the Deauville 5-point scale (5-PS). Results: With 43 months median follow-up, the 2-year Progression free survival (PFS) and Overall survival (OS) were 51% and 67%. Positive iPET2 patients (5-PS ≥4) had a significantly worse outcome than those with negative iPET2 (p

  • predictive value of pet response combined with baseline metabolic tumor volume in Peripheral t cell Lymphoma patients
    The Journal of Nuclear Medicine, 2017
    Co-Authors: Anne Segolene Cottereau, Tarec Christoffe Elgalaly, Stephanie Ecke, Florence Oussais, Lars Jelstrup Peterso, Christophe Onne, Joh O Prio, Herve Tilly, Marti Hutchings, Olivie Casasnovas
    Abstract:

    Peripheral T-Cell Lymphoma (PTCL) is a heterogeneous group of aggressive non-Hodgkin Lymphomas with poor outcomes on current therapy. We investigated whether response assessed with PET/CT combined with baseline total metabolic tumor volume (TMTV) could detect early relapse or refractory disease. Methods: From 7 European centers, 140 patients with nodal PTCL who underwent baseline PET/CT were selected. Forty-three had interim PET (iPET) performed after 2 cycles (iPET2), 95 had iPET performed after 3 or 4 cycles (iPET3/4), and 96 had end-of-treatment PET (eotPET). Baseline TMTV was computed with a 41% SUV max threshold, and PET response was reported using the Deauville 5-point scale. Results: With a median of 43 mo of follow-up, the 2-y progression-free survival (PFS) and overall survival (OS) were 51% and 67%, respectively. iPET2-positive patients (Deauville score ≥ 4) had a significantly worse outcome than iPET2-negative patients (P 230 cm 3 and iPET3/4-negative [59%/84%]; TMTV ≤ 230 cm 3 and iPET3/4-positive [42%/50%]; TMTV > 230 cm 3 and iPET3/4-positive [0%/18%]). Conclusion: iPET response is predictive of outcome and allows early detection of high-risk PTCL patients. Combining iPET with TMTV improves risk stratification in individual patients.

  • prognostic value of baseline total metabolic tumor volume tmtv0 measured on fdg pet ct in patients with Peripheral t cell Lymphoma ptcl
    Annals of Oncology, 2016
    Co-Authors: Anne Segolene Cottereau, Stephanie Ecke, Florence Oussais, Olivie Casasnovas, Salim Kanou, M Roques, N Charrie, S Ertrand, Richard Delarue, Christophe Onne
    Abstract:

    Most Peripheral T-Cell Lymphoma (PTCL) patients have a poor outcome and the identification of prognostic factors at diagnosis is needed.

  • Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with Peripheral T-Cell Lymphoma (PTCL)
    Annals of Oncology, 2016
    Co-Authors: Anne Segolene Cottereau, Olivie Casasnovas, M Roques, Richard Delarue, S. Becker, F. Broussais, S. Kanoun, N. Charrier, S. Bertrand, C. Bonnet
    Abstract:

    Most Peripheral T-Cell Lymphoma (PTCL) patients have a poor outcome and the identification of prognostic factors at diagnosis is needed.

  • Baseline Total Metabolic Tumor Volume Measured with Fixed or Different Adaptive Thresholding Methods Equally Predicts Outcome in Peripheral T Cell Lymphoma
    2016
    Co-Authors: Anne Segolene Cottereau, Herve Tilly, Olivie Casasnovas, S. Becker, Sébastien Hapdey, Romain Modzelewski, Emmanuel Itti, Pierre Vera, Michel A. Meignan, Isabelle Gardin
    Abstract:

    The purpose of this study was to compare in a large series of Peripheral T cell Lymphoma, as a model of diffuse disease, the prognostic value of baseline total metabolic tumor volume (TMTV) measured on 18F-FDG PET/CT with adaptive thresholding methods with TMTV measured with a fixed 41% SUVmax threshold method.

Olivie Casasnovas - One of the best experts on this subject based on the ideXlab platform.

  • Predictive value of PET response combined with baseline metabolic tumor volume in Peripheral T-Cell Lymphoma patients
    Journal of Nuclear Medicine, 2018
    Co-Authors: Anne Segolene Cottereau, Herve Tilly, S. Becker, F. Broussais, C. Bonnet, Tarec C El-galaly, Lars Jelstrup Peterson, John O Prior, Martin Hutchings, Olivie Casasnovas
    Abstract:

    Peripheral T-Cell Lymphoma (PTCL) is a heterogeneous group of aggressive non-Hodgkin Lymphomas with poor outcomes with current therapy. We investigated if response assessed with Positron Emission Tomography/computed tomography (PET/CT) combined with baseline total metabolic tumor volume (TMTV) could detect early relapse/refractory patients. Methods: 140 patients with nodal PTCL who underwent baseline PET/CT were selected from 7 European centers. 43 had interim PET (iPET) performed after two cycles (iPET2), 95 after 3 or 4 cycles (iPET3/4) and 96 had end of treatment PET (eotPET). Baseline TMTV was computed with 41% SUVmax threshold, and PET response was reported with the Deauville 5-point scale (5-PS). Results: With 43 months median follow-up, the 2-year Progression free survival (PFS) and Overall survival (OS) were 51% and 67%. Positive iPET2 patients (5-PS ≥4) had a significantly worse outcome than those with negative iPET2 (p

  • predictive value of pet response combined with baseline metabolic tumor volume in Peripheral t cell Lymphoma patients
    The Journal of Nuclear Medicine, 2017
    Co-Authors: Anne Segolene Cottereau, Tarec Christoffe Elgalaly, Stephanie Ecke, Florence Oussais, Lars Jelstrup Peterso, Christophe Onne, Joh O Prio, Herve Tilly, Marti Hutchings, Olivie Casasnovas
    Abstract:

    Peripheral T-Cell Lymphoma (PTCL) is a heterogeneous group of aggressive non-Hodgkin Lymphomas with poor outcomes on current therapy. We investigated whether response assessed with PET/CT combined with baseline total metabolic tumor volume (TMTV) could detect early relapse or refractory disease. Methods: From 7 European centers, 140 patients with nodal PTCL who underwent baseline PET/CT were selected. Forty-three had interim PET (iPET) performed after 2 cycles (iPET2), 95 had iPET performed after 3 or 4 cycles (iPET3/4), and 96 had end-of-treatment PET (eotPET). Baseline TMTV was computed with a 41% SUV max threshold, and PET response was reported using the Deauville 5-point scale. Results: With a median of 43 mo of follow-up, the 2-y progression-free survival (PFS) and overall survival (OS) were 51% and 67%, respectively. iPET2-positive patients (Deauville score ≥ 4) had a significantly worse outcome than iPET2-negative patients (P 230 cm 3 and iPET3/4-negative [59%/84%]; TMTV ≤ 230 cm 3 and iPET3/4-positive [42%/50%]; TMTV > 230 cm 3 and iPET3/4-positive [0%/18%]). Conclusion: iPET response is predictive of outcome and allows early detection of high-risk PTCL patients. Combining iPET with TMTV improves risk stratification in individual patients.

  • prognostic value of baseline total metabolic tumor volume tmtv0 measured on fdg pet ct in patients with Peripheral t cell Lymphoma ptcl
    Annals of Oncology, 2016
    Co-Authors: Anne Segolene Cottereau, Stephanie Ecke, Florence Oussais, Olivie Casasnovas, Salim Kanou, M Roques, N Charrie, S Ertrand, Richard Delarue, Christophe Onne
    Abstract:

    Most Peripheral T-Cell Lymphoma (PTCL) patients have a poor outcome and the identification of prognostic factors at diagnosis is needed.

  • Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with Peripheral T-Cell Lymphoma (PTCL)
    Annals of Oncology, 2016
    Co-Authors: Anne Segolene Cottereau, Olivie Casasnovas, M Roques, Richard Delarue, S. Becker, F. Broussais, S. Kanoun, N. Charrier, S. Bertrand, C. Bonnet
    Abstract:

    Most Peripheral T-Cell Lymphoma (PTCL) patients have a poor outcome and the identification of prognostic factors at diagnosis is needed.

  • Baseline Total Metabolic Tumor Volume Measured with Fixed or Different Adaptive Thresholding Methods Equally Predicts Outcome in Peripheral T Cell Lymphoma
    2016
    Co-Authors: Anne Segolene Cottereau, Herve Tilly, Olivie Casasnovas, S. Becker, Sébastien Hapdey, Romain Modzelewski, Emmanuel Itti, Pierre Vera, Michel A. Meignan, Isabelle Gardin
    Abstract:

    The purpose of this study was to compare in a large series of Peripheral T cell Lymphoma, as a model of diffuse disease, the prognostic value of baseline total metabolic tumor volume (TMTV) measured on 18F-FDG PET/CT with adaptive thresholding methods with TMTV measured with a fixed 41% SUVmax threshold method.

Mark R. Pittelkow - One of the best experts on this subject based on the ideXlab platform.

  • T-Cell receptor gene rearrangement analysis: Cutaneous T cell Lymphoma, Peripheral T cell Lymphoma, and premalignant and benign cutaneous lymphoproliferative disorders
    Journal of The American Academy of Dermatology, 1991
    Co-Authors: Brian D Zelickson, S A Muller, L M Quam, M. S. Peters, John A Lust, Stephen N Thibodeau, Mark R. Pittelkow
    Abstract:

    T-Cell receptor gene rearrangement analysis is a useful technique to detect clonality and determine lineage of lymphoid neoplasms. We examined 103 patients with mycosis fungoides, Sezary syndrome, Peripheral T cell Lymphoma, potentially malignant lymphoproliferative disorders including pre-Sezary syndrome, large plaque parapsoriasis, Lymphomatoid papulosis and follicular mucinosis, and various benign inflammatory infiltrates. A clonal rearrangement was detected in skin samples in 20 of 24 patients with mycosis fungoides and in Peripheral blood samples in 19 of 21 patients with Sezary syndrome. A clonal population was also detected in seven of eight cases classified as Peripheral T cell Lymphoma. The potentially malignant dermatoses tended to have clonal rearrangement, with the exception of large plaque parapsoriasis, and further follow-up is needed to correlate clonality with the disease course. These studies demonstrate the value of molecular genetics as an adjunct to morphology in the examination of patients with cutaneous lymphoproliferative disease.

  • T-Cell receptor gene rearrangement analysis: cutaneous T cell Lymphoma, Peripheral T cell Lymphoma, and premalignant and benign cutaneous lymphoproliferative disorders.
    Journal of the American Academy of Dermatology, 1991
    Co-Authors: Brian D Zelickson, S A Muller, L M Quam, M. S. Peters, John A Lust, Stephen N Thibodeau, Mark R. Pittelkow
    Abstract:

    T-Cell receptor gene rearrangement analysis is a useful technique to detect clonality and determine lineage of lymphoid neoplasms. We examined 103 patients with mycosis fungoides, Sézary syndrome, Peripheral T cell Lymphoma, potentially malignant lymphoproliferative disorders including pre-Sézary syndrome, large plaque parapsoriasis, Lymphomatoid papulosis and follicular mucinosis, and various benign inflammatory infiltrates. A clonal rearrangement was detected in skin samples in 20 of 24 patients with mycosis fungoides and in Peripheral blood samples in 19 of 21 patients with Sézary syndrome. A clonal population was also detected in seven of eight cases classified as Peripheral T cell Lymphoma. The potentially malignant dermatoses tended to have clonal rearrangement, with the exception of large plaque parapsoriasis, and further follow-up is needed to correlate clonality with the disease course. These studies demonstrate the value of molecular genetics as an adjunct to morphology in the examination of patients with cutaneous lymphoproliferative disease.

C. Bonnet - One of the best experts on this subject based on the ideXlab platform.

  • Predictive value of PET response combined with baseline metabolic tumor volume in Peripheral T-Cell Lymphoma patients
    Journal of Nuclear Medicine, 2018
    Co-Authors: Anne Segolene Cottereau, Herve Tilly, S. Becker, F. Broussais, C. Bonnet, Tarec C El-galaly, Lars Jelstrup Peterson, John O Prior, Martin Hutchings, Olivie Casasnovas
    Abstract:

    Peripheral T-Cell Lymphoma (PTCL) is a heterogeneous group of aggressive non-Hodgkin Lymphomas with poor outcomes with current therapy. We investigated if response assessed with Positron Emission Tomography/computed tomography (PET/CT) combined with baseline total metabolic tumor volume (TMTV) could detect early relapse/refractory patients. Methods: 140 patients with nodal PTCL who underwent baseline PET/CT were selected from 7 European centers. 43 had interim PET (iPET) performed after two cycles (iPET2), 95 after 3 or 4 cycles (iPET3/4) and 96 had end of treatment PET (eotPET). Baseline TMTV was computed with 41% SUVmax threshold, and PET response was reported with the Deauville 5-point scale (5-PS). Results: With 43 months median follow-up, the 2-year Progression free survival (PFS) and Overall survival (OS) were 51% and 67%. Positive iPET2 patients (5-PS ≥4) had a significantly worse outcome than those with negative iPET2 (p

  • Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with Peripheral T-Cell Lymphoma (PTCL)
    Annals of Oncology, 2016
    Co-Authors: Anne Segolene Cottereau, Olivie Casasnovas, M Roques, Richard Delarue, S. Becker, F. Broussais, S. Kanoun, N. Charrier, S. Bertrand, C. Bonnet
    Abstract:

    Most Peripheral T-Cell Lymphoma (PTCL) patients have a poor outcome and the identification of prognostic factors at diagnosis is needed.

Christophe Onne - One of the best experts on this subject based on the ideXlab platform.

  • predictive value of pet response combined with baseline metabolic tumor volume in Peripheral t cell Lymphoma patients
    The Journal of Nuclear Medicine, 2017
    Co-Authors: Anne Segolene Cottereau, Tarec Christoffe Elgalaly, Stephanie Ecke, Florence Oussais, Lars Jelstrup Peterso, Christophe Onne, Joh O Prio, Herve Tilly, Marti Hutchings, Olivie Casasnovas
    Abstract:

    Peripheral T-Cell Lymphoma (PTCL) is a heterogeneous group of aggressive non-Hodgkin Lymphomas with poor outcomes on current therapy. We investigated whether response assessed with PET/CT combined with baseline total metabolic tumor volume (TMTV) could detect early relapse or refractory disease. Methods: From 7 European centers, 140 patients with nodal PTCL who underwent baseline PET/CT were selected. Forty-three had interim PET (iPET) performed after 2 cycles (iPET2), 95 had iPET performed after 3 or 4 cycles (iPET3/4), and 96 had end-of-treatment PET (eotPET). Baseline TMTV was computed with a 41% SUV max threshold, and PET response was reported using the Deauville 5-point scale. Results: With a median of 43 mo of follow-up, the 2-y progression-free survival (PFS) and overall survival (OS) were 51% and 67%, respectively. iPET2-positive patients (Deauville score ≥ 4) had a significantly worse outcome than iPET2-negative patients (P 230 cm 3 and iPET3/4-negative [59%/84%]; TMTV ≤ 230 cm 3 and iPET3/4-positive [42%/50%]; TMTV > 230 cm 3 and iPET3/4-positive [0%/18%]). Conclusion: iPET response is predictive of outcome and allows early detection of high-risk PTCL patients. Combining iPET with TMTV improves risk stratification in individual patients.

  • prognostic value of baseline total metabolic tumor volume tmtv0 measured on fdg pet ct in patients with Peripheral t cell Lymphoma ptcl
    Annals of Oncology, 2016
    Co-Authors: Anne Segolene Cottereau, Stephanie Ecke, Florence Oussais, Olivie Casasnovas, Salim Kanou, M Roques, N Charrie, S Ertrand, Richard Delarue, Christophe Onne
    Abstract:

    Most Peripheral T-Cell Lymphoma (PTCL) patients have a poor outcome and the identification of prognostic factors at diagnosis is needed.